ZNF155 Inhibitors
Chemical inhibitors of ZNF155 employ various mechanisms to suppress its activity within cellular processes. Chelerythrine and Ro-31-8220, both known as protein kinase C (PKC) inhibitors, directly impact ZNF155 by preventing its phosphorylation-a critical post-translational modification that can activate or deactivate many proteins. By inhibiting PKC, these chemicals can restrain the phosphorylation state of ZNF155, thereby reducing its functional activity. Similarly, PD 98059 and U0126, as selective inhibitors of mitogen-activated protein kinase kinase (MEK), can influence ZNF155 by targeting the MAPK/ERK pathway, a signaling route often associated with the regulation of various proteins. The inhibition of MEK by these compounds results in a diminished activation of ZNF155, leading to a lower level of its activity.
Furthermore, LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases (PI3K), can alter ZNF155 activity by interrupting PI3K-dependent signaling pathways. Since PI3K plays a substantial role in regulating numerous proteins, its inhibition by these chemicals can lead to a decrease in ZNF155 function. SB 203580, by specifically targeting p38 MAP kinase, and SP600125, by inhibiting c-Jun N-terminal kinase (JNK), can also modulate ZNF155 activity. These kinases are part of distinct cellular signaling pathways that have the capacity to control the function of ZNF155, and their inhibition can therefore reduce ZNF155's activity. Staurosporine, a broad-spectrum kinase inhibitor, can affect various protein kinases that might interact with ZNF155, leading to a comprehensive reduction in its activity. Lastly, Trichostatin A, by inhibiting histone deacetylases, can change the chromatin structure and thus the DNA binding affinity of ZNF155, while Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can indirectly influence the cellular environment of ZNF155. Thapsigargin, a SERCA pump inhibitor, disrupts calcium-dependent signaling pathways, which can have a downstream effect on the regulation of ZNF155's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C (PKC), which is involved in a wide range of cellular processes. By inhibiting PKC, chelerythrine can reduce the phosphorylation of ZNF155, thereby inhibiting its function. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220 is another PKC inhibitor that could restrict the phosphorylation of ZNF155, a post-translational modification that might be crucial for ZNF155's activity, hence inhibiting the protein's functionality. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting this pathway, PD 98059 could reduce the activation state of ZNF155, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling can regulate a variety of proteins, including ZNF155. Inhibition by LY294002 could reduce ZNF155 activity through alterations in PI3K-dependent signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 specifically inhibits p38 MAP kinase, which might be involved in the phosphorylation and subsequent regulation of ZNF155. By inhibiting p38 MAP kinase, SB 203580 could lead to a decrease in ZNF155 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which may interact with ZNF155 as part of cellular signaling cascades. By blocking JNK, SP600125 could impede the regulatory effects on ZNF155, leading to functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor like LY294002 and can inhibit ZNF155 by a similar mechanism, disrupting PI3K-dependent pathways that may control ZNF155's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a central regulator of cell growth and proliferation. Through mTOR inhibition, rapamycin can indirectly inhibit ZNF155 function by impacting the cellular context in which ZNF155 operates. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor and can alter chromatin structure, thereby potentially changing the binding landscape for ZNF155 on DNA and inhibiting its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK like PD 98059 and can inhibit ZNF155 by reducing its activation in the MAPK/ERK pathway, leading to decreased functional activity of ZNF155. | ||||||